French drug maker Sanofi says its bottom line was roughly stable last year as it advanced efforts to reshape its drug portfolio and pursue research and development tie-ups in oncology and diabetes.
Sanofi made 4.29 billion euros ($4.8 billion) last year, compared to 4.39 billion in 2014. ın a statement, Sanofi said it "made meaningful progress with key launches, multiple business development activities and our efforts to simplify the organization." ın December Sanofi and German pharmaceutical company Boehringer ıngelheim said they are pursuing an asset swap that would see the German firm take over Sanofi's Merial animal health unit, which is valued at 11.4 billion euros. Sanofi is to acquire a large part of Boehringer's consumer health care business.
Keep up to date with what’s happening in Turkey,
it’s region and the world.
You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Please
click
to read our informative text prepared pursuant to the Law on the Protection of Personal Data No. 6698 and to get information about the
cookies
used on our website in accordance with the relevant legislation.
6698 sayılı Kişisel Verilerin Korunması Kanunu uyarınca hazırlanmış aydınlatma metnimizi okumak ve sitemizde ilgili mevzuata uygun olarak kullanılan
çerezlerle
ilgili bilgi almak için lütfen
tıklayınız.